Translating Efficacy of Liver Transplantation in Liver-limited Metastatic Colorectal Cancer into Clinical Practice: the TransMet Trial

Overview

Journal ESMO Open

Publisher Elsevier

Specialty Oncology

Date 2024 Sep 28

PMID 39341646

Authors

M M Germani

N Raschzok

V Heinemann

D P Modest

Affiliations

Soon will be listed here.

Abstract

Pioneer studies suggested that liver transplantation (LT) has the potential to provide long-term survival in patients with liver-limited metastatic colorectal cancer (mCRC) not amenable for surgery of metastases. Evidence, however, was limited to single-arm studies with few patients enrolled and suboptimal selection criteria, with concerns over access to organ availability overcoming the potential efficacy of LT in this setting. Recently, 5-year survival rates with chemotherapy followed by LT (73%) compared with chemotherapy alone (9%) have been demonstrated by the randomized TransMet trial, enrolling 94 definitively unresectable strictly selected liver-limited mCRC patients. These findings should now prompt clinical oncologists to reconsider LT as a valuable option for unresectable liver-limited mCRC patients meeting TransMet criteria, and transplantation agencies to adapt their policies of access to organ donation.

References

Wang B, Shubin A, Harvey J, MacConmara M, Hwang C, Patel M . From Patients to Providers: Assessing Impact of Normothermic Machine Perfusion on Liver Transplant Practices in the US. J Am Coll Surg. 2023; 238(5):844-852. DOI: 10.1097/XCS.0000000000000924. View

Bond M, Bolhuis K, Loosveld O, de Groot J, Droogendijk H, Helgason H . First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Lancet Oncol. 2023; 24(7):757-771. DOI: 10.1016/S1470-2045(23)00219-X. View

Belli L, Perricone G, Adam R, Cortesi P, Strazzabosco M, Facchetti R . Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018; 69(4):810-817. DOI: 10.1016/j.jhep.2018.06.010. View

Moosburner S, Patel M, Wang B, Prasadh J, Ollinger R, Lurje G . Multinational Analysis of Marginal Liver Grafts Based on the Eurotransplant Extended Donor Criteria. Ann Surg. 2024; 280(5):896-904. DOI: 10.1097/SLA.0000000000006491. View

Umgelter A, Hapfelmeier A, Kopp W, van Rosmalen M, Rogiers X, Guba M . Disparities in Eurotransplant liver transplantation wait-list outcome between patients with and without model for end-stage liver disease exceptions. Liver Transpl. 2017; 23(10):1256-1265. DOI: 10.1002/lt.24805. View

Bonney G, Chew C, Lodge P, Hubbard J, Halazun K, Trunecka P . Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines. Lancet Gastroenterol Hepatol. 2021; 6(11):933-946. DOI: 10.1016/S2468-1253(21)00219-3. View

Dueland S, Yaqub S, Syversveen T, Carling U, Hagness M, Brudvik K . Survival Outcomes After Portal Vein Embolization and Liver Resection Compared With Liver Transplant for Patients With Extensive Colorectal Cancer Liver Metastases. JAMA Surg. 2021; 156(6):550-557. PMC: 8014205. DOI: 10.1001/jamasurg.2021.0267. View

Moretto R, Germani M, Borelli B, Conca V, Rossini D, Boraschi P . Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience. ESMO Open. 2024; 9(4):102991. PMC: 11027482. DOI: 10.1016/j.esmoop.2024.102991. View

Ros J, Salva F, Dopazo C, Lopez D, Saoudi N, Baraibar I . Liver transplantation in metastatic colorectal cancer: are we ready for it?. Br J Cancer. 2023; 128(10):1797-1806. PMC: 10147684. DOI: 10.1038/s41416-023-02213-1. View

10.

Adam R, Badrudin D, Chiche L, Bucur P, Scatton O, Granger V . Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial. EClinicalMedicine. 2024; 72:102608. PMC: 11077272. DOI: 10.1016/j.eclinm.2024.102608. View

11.

Solheim J, Dueland S, Line P, Hagness M . Transplantation for Nonresectable Colorectal Liver Metastases: Long-Term Follow-Up of the First Prospective Pilot Study. Ann Surg. 2022; 278(2):239-245. DOI: 10.1097/SLA.0000000000005703. View

12.

Dueland S, Grut H, Syversveen T, Hagness M, Line P . Selection criteria related to long-term survival following liver transplantation for colorectal liver metastasis. Am J Transplant. 2019; 20(2):530-537. DOI: 10.1111/ajt.15682. View

13.

Modest D, Heinemann V, Folprecht G, Denecke T, Pratschke J, Lang H . Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOKRK0306. Ann Surg Oncol. 2020; 27(7):2389-2401. PMC: 7311511. DOI: 10.1245/s10434-020-08219-w. View

14.

Dueland S, Syversveen T, Solheim J, Solberg S, Grut H, Bjornbeth B . Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases. Ann Surg. 2019; 271(2):212-218. DOI: 10.1097/SLA.0000000000003404. View

15.

Lozanovski V, Probst P, Ramouz A, Arefidoust A, Ghamarnejad O, Aminizadeh E . Considering extended right lobe grafts as major extended donor criteria in liver transplantation is justified. Transpl Int. 2021; 34(4):622-639. DOI: 10.1111/tri.13824. View

16.

Cervantes A, Adam R, Rosello S, Arnold D, Normanno N, Taieb J . Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022; 34(1):10-32. DOI: 10.1016/j.annonc.2022.10.003. View